OPTec: Outpatient Step Up Administration of Teclistamab: Implications in Real-World Practice

Data from the phase 3 AQUILA study support the FDA approval of subcutaneous daratumumab in this population with smoldering multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Investigators are currently assessing the antibody-drug conjugate HDP-101 as part of a phase 1/2a study.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.